Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

NCT02520245 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies

Interventions

DRUG: REGN2810

Sponsor

Regeneron Pharmaceuticals